News

Collaboration combines expertise in computational chemistry, artificial intelligence and machine learning, to help advance discovery and development of medicines for difficult-to-drug targets

BOSTON, April 4, 2024 — Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets. The companies will combine their expertise in artificial intelligence (AI), machine learning (ML), computational chemistry and drug discovery to unlock difficult-to-drug targets. The agreement was facilitated by Johnson & Johnson Innovation.

Since its founding in 2021, Odyssey has assembled a team of expert drug hunters with deep experience in immunology, oncology, medicinal chemistry and structural biophysics, and armed them with next-generation computational tools to solve difficult therapeutic challenges. This integration of in silico methods, cutting-edge experimental capabilities, and wet lab infrastructure enables the scientists at Odyssey to rapidly discover and develop potentially transformative medicines for patients.

“We are excited about this collaboration to push the boundaries of the drug discovery and development process, using the latest advancements in AI and ML to find solutions for serious diseases,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “This collaboration between our chemists, biologists, and data scientists will help accelerate our joint drug discovery efforts through optimization of our tools, data sharing, and model development to discover and develop transformational medicines for patients in need.”

Under the terms of the agreement, Odyssey will work with discovery and therapeutic area experts and data scientists at Johnson & Johnson to deploy AI and ML to discover and optimize small molecule therapeutics against multiple targets. Odyssey will receive an upfront payment and is eligible for milestone payments and royalties.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next-generation of immunomodulators and oncology medicines. Composed of an expert team of drug hunters, scientists and industry leaders in foundational biology, chemistry and data sciences, Odyssey is transforming drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.

Media Contact

Josh George
[email protected]
503-799-7520